VANCOUVER -- ID Biomedical reported today that it has data demonstrating protection against variant strains of influenza.
Results from pre-clinical experiments performed by ID Biomedical scientists and recently published in the September 2003 issue of the peer reviewed journal, Vaccine, provides evidence that nasal Proteosome -- influenza subunit vaccines can protect against infection by variant strains of influenza virus that have 'drifted' from the strain present in the vaccine. In the study reported by Jones et al. in Vaccine vol. 21 pp. 3706-3712, mice were given a nasal Proteosome-influenza vaccine containing a recombinant influenza hemagglutinin (HA) from the A/Texas H1 subtype of influenza. Mice were then exposed to a lethal dose of a mouse-adapted A/Taiwan H1 strain of influenza virus which was not present in the trivalent composition of the vaccine. The A/Taiwan and A/Texas strains represent drift variants within the H1 subtype.
Nasal immunization with the subunit Proteosome-A/Texas vaccine protected 100 percent of the mice against mortality and weight loss (a sign of clinical illness) following exposure to the live A/Taiwan drift variant virus. The same challenge dose of live A/Taiwan virus caused 100 percent mortality in non-vaccinated control animals. Mice that received an intramuscular vaccination with the same dose of A/Texas HA (not formulated as a Proteosome-HA vaccine) were also protected against death following exposure to the live drift variant virus but experienced significant illness as demonstrated by a 13 percent loss in weight. Only the nasal Proteosome-HA subunit vaccine induced detectable mucosal IgA in the respiratory tract which may explain the enhanced cross-protection shown by the mucosally-delivered Proteosome-subunit influenza vaccine.
"This flu season we have a similar situation. Flu vaccines including FluINsure have been designed to protect against the A/Panama strain of influenza but the predominant strain causing influenza appears to be A/Fujian, a variant of the A/Panama strain." David Burt ID Biomedical's vice president of research stated. "These pre-clinical findings suggest that FluINsure may also protect humans against drift variant strains of influenza which are in circulation and which are not identical but are closely related to the strain present in the vaccine."
FluINsure, ID Biomedical's nasal Proteosome-influenza subunit vaccine is currently being tested in a 1,345 subject field efficacy study. In phase II clinical trials, FluINsure protected human volunteers against laboratory confirmed influenza following experimental challenge with a strain of live influenza virus which was identical to one of the three strains represented in the vaccine.
ID Biomedical is a biotechnology company focused on the development of proprietary subunit vaccine products, including those based on its Proteosome platform intranasal adjuvant/delivery technology.
Source: ID Biomedical Corporation
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.